STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
STAT [Unofficial]
June 9, 2026
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Discussion in the ATmosphere